Home > Press > BioSante Pharmaceuticals Common Stock To Begin Trading On NASDAQ Global Market on Monday, November 5, 2007
Abstract:
BioSante Pharmaceuticals, Inc. (AMEX: BPA) today announced that its common stock will commence trading on the NASDAQ Global Market (NASDAQ) effective Monday, November 5, 2007 under the new ticker symbol "BPAX". BioSante announced on October 23, 2007 its intention to transfer its common stock listing from The American Stock Exchange (Amex) to the NASDAQ. All appropriate filings have been made by BioSante to effect the transfer, including a timely request to delist from Amex.
BioSante Pharmaceuticals Common Stock To Begin Trading On NASDAQ Global Market on Monday, November 5, 2007
LINCOLNSHIRE, IL | Posted on November 2nd, 2007
About NASDAQ
NASDAQ® is the largest U.S. electronic stock market. With approximately 3,100 companies, it lists more companies and, on average, its systems trade more shares per day than any other U.S. market. NASDAQ is home to companies that are leaders across all areas of business including technology, retail, communications, financial services, transportation, media and biotechnology. NASDAQ is the primary market for trading NASDAQ-listed stocks. For more information about NASDAQ, visit the NASDAQ website at http://www.nasdaq.com or the NASDAQ NewsroomSM at http://www.nasdaq.com/newsroom .
####
About BioSante Pharmaceuticals, Inc.
BioSante is developing a pipeline of hormone therapy products to treat both men and women. These hormone therapy products are gel formulations for transdermal administration that deliver bioidentical estradiol and testosterone. BioSante's lead products include Elestrin™ (estradiol gel) developed through U.S. Food and Drug Administration (FDA) approval by BioSante indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, marketed in the U.S. by Bradley Pharmaceuticals, Inc., BioSante's licensee, and LibiGel® (transdermal testosterone gel) in Phase III clinical development by BioSante for the treatment of female sexual dysfunction (FSD). Also in development are Bio-T-Gel™, a testosterone gel for male hypogonadism, and an oral contraceptive in Phase II clinical development using BioSante patented technology. The current market in the U.S. for estrogen and testosterone products is approximately $2.5 billion and for oral contraceptives approximately $3.0 billion. The company also is developing its calcium phosphate nanotechnology (CaP) for novel vaccines, drug delivery, and aesthetic medicine.
For more information, please click here
Contacts:
McKinney/Chicago
Alan Zachary, (312) 944-6784 ext. 316
http://www.mckinneychicago.com
Copyright © Business Wire 2007
If you have a comment, please
Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Bookmark:
Investments/IPO's/Splits
QWave Fund Powers Physics and Materials Science-Based Innovation With Initial Round of Venture Capital Investments: New VC Fund Invests Total of $7M in Nano-Meta Technologies, Centice and Clifton June 19th, 2013
Nanometrics Announces Participation in 5th Annual CEO Investor Summit: Accredited Investor and Publishing Research Analyst Event to be Held Concurrently With SEMICON West and Intersolar 2013 in San Francisco June 19th, 2013
Dr. Ben J. Lipps designated as Chairman of the Management Board and Chief Executive Officer of Nanostart-holding MagForce AG June 17th, 2013
Harris & Harris Group Notes Carl Zeiss' Planned Acquisition of Xradia June 13th, 2013
Nanomedicine
Production of Bioactive Material for Quick Treatment of Bone Damages June 19th, 2013
3-D printing could lead to tiny medical implants, electronics, robots, more June 18th, 2013
Pioneering breakthrough of chemical nanoengineering to design drugs controlled by light June 18th, 2013
Study Shows How the Nanog Protein Promotes Growth of Head and Neck Cancer June 18th, 2013
Announcements
Less is More: Novel Cellulose Structure Requires Fewer Enzymes to Process Biomass to Fuel June 19th, 2013
Sound waves precisely position nanowires June 19th, 2013
Scientists Use Nanotechnology to Increase Thermal Stability of Essential Oils June 19th, 2013
Production of Bioactive Material for Quick Treatment of Bone Damages June 19th, 2013